clinical trial · NCT07850635
A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany·phase1·not yet recruiting·n = 6
Neurofibromatosis Type 1-Associated Plexiform NeurofibromasMirdametinib
brief summary
The purpose of this study is to determine the safety, pharmacokinetic (PK), and tolerability of multiple treatment cycles of oral mirdametinib in infants and toddlers (0 to less than \[\<\] 24 months of age) with measurable neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PNs) that is symptomatic or asymptomatic but in a high-risk location with a high risk of morbidity.
started
Dec 9, 2026
primary completion
Oct 21, 2032
completion
Oct 21, 2032
last updated
Oct 21, 2026
official title
A Phase 1b, Open-Label Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol